Company: SCLXW
Filing Date: 2025-05-14
Form Type: 424B3
Source: 0001193125-25-119846
Chunk: 77

Company: Scilex Holding Co
Filing Date: 2025-05-14
Form: 424B3
Chunk 77
---
 legislation impacting the workforce, such as the proposed rule published by the Federal Trade Commission which would, if issued, generally prevent employers from entering into non-competeagreements with employees and require employers to rescind existing non-competeagreements, may lead to increased uncertainty in hiring and competition for talent. Further, we may experience employee turnover as a result of the ongoing “great resignation” occurring throughout the U.S. economy, which has impacted job market dynamics. New hires require training and take time before they achieve full productivity. New employees may not become as productive as we expect, and we may be unable to hire or retain sufficient numbers of qualified individuals. Moreover, we conduct our operations in the San Francisco Bay Area, a region that is home to many other biopharmaceutical companies as well as many academic and research institutions, resulting in fierce competition for qualified personnel. As such, we could have difficulty attracting and retaining experienced executives and may be required to expend significant financial resources in our recruitment and retention efforts. We may need to increase the size of our company and may not effectively manage our growth. As of December 31, 2024, we had approximately 115 full-time employees. We may need to continue to expand our managerial, operational, sales and marketing, finance and other resources in order to manage our operations, clinical trials, research and development activities, regulatory filings, manufacturing and supply activities, and any marketing and commercialization activities, including co-promotionactivities. Future growth would impose significant added responsibilities on members of management, including:

| • |     | identifying, recruiting, integrating, maintaining and motivating additional employees; |

| • |     | managing our internal development efforts effectively, including the clinical, FDA and internal regulatory review                
 process for our product candidates, while complying with our contractual obligations to contractors and other third parties; and |

| • |     | improving our operational, financial and management controls, reporting systems and procedures. |

47

Our future financial performance and our ability to commercialize our product candidates
will depend, in part, on our ability to effectively manage any future growth, if any, which may cause a significant strain on our management, and our operational, financial and other resources. Our ability to manage our growth effectively will
require us to implement and improve our operational, financial and management systems and to expand, train, manage and motivate our employees. These demands may require the hiring of additional management personnel and the development of additional
expertise by management. Any increase in resources devoted to research and product development without a